Endostatin

Summary

Endostatin (CHEMBL4297747) is a phase-3 clinical-stage unknown; indicated across 10 conditions including non-small cell lung carcinoma and nasopharyngeal neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 10 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297747
Name	Endostatin
Type	Unknown
Max phase	3

Also known as: Endostatin, YH 16, YH-16, ENDOSTATIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
nasopharyngeal neoplasm	2	MONDO:0005375	EFO:0004252
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
neoplasm	2	MONDO:0005070	EFO:0000616
melanoma	2	MONDO:0005105	EFO:0000756
colorectal neoplasm	2	MONDO:0005335	EFO:0004142
upper aerodigestive tract neoplasm	2	MONDO:0005398	EFO:0004284
lung neoplasm	2	MONDO:0021117	MONDO:0008903
nasopharyngeal carcinoma	2	MONDO:0015459	MONDO:0015459
glioma	2	MONDO:0021042	MONDO:0021637

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	8
PHASE4	1
PHASE2/PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02497118	PHASE4	COMPLETED	Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
NCT01689558	PHASE2/PHASE3	UNKNOWN	Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer
NCT05514275	PHASE2	RECRUITING	Radiotherapy Combined With Endostatin and Capecitabine for NPC
NCT01218594	PHASE2	UNKNOWN	Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer
NCT01347424	PHASE2	UNKNOWN	Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography
NCT01612286	PHASE2	UNKNOWN	Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma
NCT01845675	PHASE2	COMPLETED	Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor
NCT02104323	PHASE2	COMPLETED	Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NCT05448781	PHASE2	UNKNOWN	Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC
NCT06047860	PHASE2	UNKNOWN	A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
NCT00262327	PHASE1	UNKNOWN	Safety and Efficacy of Adenoviral Endostatin in the Treatment of Advanced Solid Tumor

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).